PFG Investments’s Sarepta Therapeutics SRPT Stock Holding History

PFG Investments’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$375K	Hold	20,843	–	–	0.01%	821
2026 Q1	$454K	Sell	20,843 -1,200	-5%	-$23.2K	0.02%	646
2025 Q4	$474K	Sell	22,043 -2,500	-10%	-$52.7K	0.02%	590
2025 Q3	$473K	Sell	24,543 -890	-3%	-$15.9K	0.02%	566
2025 Q2	$435K	Sell	25,433 -1,000	-4%	-$42.7K	0.03%	579
2025 Q1	$1.69M	Sell	26,433 -565	-2%	-$59.5K	0.11%	190
2024 Q4	$3.28M	Buy	26,998 +324	+1%	+$39.7K	0.2%	88
2024 Q3	$3.33M	Buy	26,674 +2,145	+9%	+$297K	0.22%	83
2024 Q2	$3.88M	Buy	24,529 +434	+2%	+$55.8K	0.28%	70
2024 Q1	$3.12M	Buy	24,095 +4,610	+24%	+$565K	0.19%	111
2023 Q4	$1.88M	Sell	19,485 -2,045	-9%	-$196K	0.35%	57
2023 Q3	$2.61M	Buy	21,530 +1,100	+5%	+$124K	0.49%	35
2023 Q2	$2.34M	Buy	20,430 +1,075	+6%	+$139K	0.42%	46
2023 Q1	$2.67M	Buy	+19,355	New	+$2.51M	0.54%	31

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PFG Investments's SRPT Position: Q2 2026 in Review

PFG Investments held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 20,843 shares worth $375K. The position accounts for 0.01% of the portfolio, ranked #821.

PFG Investments first reported a position in SRPT in Q1 2023 and has held it in 14 quarters since. The position peaked at $3.88M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

PFG Investments held 20,843 shares of Sarepta Therapeutics worth $375K as of Q2 2026.
PFG Investments left its Sarepta Therapeutics share count unchanged in Q2 2026.
Sarepta Therapeutics made up 0.01% of PFG Investments's portfolio in Q2 2026, its #821 holding.
PFG Investments first reported a position in Sarepta Therapeutics in Q1 2023 and has held it in 14 quarters since.
PFG Investments's Sarepta Therapeutics position peaked at $3.88M in Q2 2024.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on PFG Investments's 13F filing for Q2 2026, filed 23 Jul 2026.